CUTANEOUS AND SEROLOGIC SUBSETS OF SYSTEMIC-SCLEROSIS

被引:0
|
作者
FERRI, C [1 ]
BERNINI, L [1 ]
CECCHETTI, R [1 ]
LATORRACA, A [1 ]
MAROTTA, G [1 ]
PASERO, G [1 ]
NERI, R [1 ]
BOMBARDIERI, S [1 ]
机构
[1] UNIV PISA,IMMUNOL UNIT,I-56100 PISA,ITALY
关键词
SYSTEMIC SCLEROSIS; CUTANEOUS SUBSETS; ANTICENTROMERE ANTIBODY; ANTI-SCL-70; ANTIBODY; SCLERODERMA SURVIVAL;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The relevance of the extent of skin sclerosis and of other clinicoserological features in diagnosis, severity and prognosis of disease was studied in a large number of unselected patients with systemic sclerosis (SSc). One hundred and fifty-one patients with SSc (126 F and 25 M, mean age 48 +/- 14 SD) followed for 5.3 +/- 3.2 years were included. Patients were divided into 3 cutaneous subsets: limited (68), intermediate (46) and diffuse SSc (37). Serological markers were detected in 288 patients with Raynaud's phenomenon and other connective tissue diseases (CTD). Limited and intermediate SSc prevailed in female patients while the diffuse subset was more frequent in males (p < 0.0001). Duration of Raynaud's phenomenon before disease onset was shorter in the diffuse variant (p < 0.0001). A wider cutaneous involvement was associated with more severe forms of SSc. Diffuse subset showed the poorest prognosis at 10 years of followup compared with intermediate (p < 0.05) and limited variant (p < 0.001). Intermediate SSc seems a distinct variant of SSc on the basis of clinical manifestations and survival. Among serological markers, anticentromere, anti-Scl-70 and antinucleolar antibodies were found in 21, 40 and 27% of the cases, respectively; these were statistically less frequent (p < 0.0001) in other CTD. In 83.5% of patients with SSc at least one of these specific markers was recorded. Anticentromere antibodies were correlated to sex (female), limited SSc, calcinosis and telangiectasia. On the contrary anti-Scl-70 was associated with diffuse and intermediate subsets and with more severe SSc manifestations. Our results underline the clinical and prognostic usefulness of cutaneous subsets in patients with scleroderma and the diagnostic value of the serological markers.
引用
收藏
页码:1826 / 1832
页数:7
相关论文
共 50 条
  • [31] IMPOTENCE IN SYSTEMIC-SCLEROSIS
    SUKENIK, S
    HOROWITZ, J
    BUSKILA, D
    ABARBANEL, JM
    LISMER, L
    AVINOACH, I
    [J]. ANNALS OF INTERNAL MEDICINE, 1987, 106 (06) : 910 - 911
  • [32] CANCER IN SYSTEMIC-SCLEROSIS
    ABUSHAKRA, M
    GUILLEMIN, F
    LEE, P
    [J]. ARTHRITIS AND RHEUMATISM, 1993, 36 (04): : 460 - 464
  • [33] PROGNOSIS OF SYSTEMIC-SCLEROSIS
    ROWELL, NR
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 1976, 95 (01) : 57 - 60
  • [34] CYTOKINES AND SYSTEMIC-SCLEROSIS
    FAGUNDUS, DM
    LEROY, EC
    [J]. CLINICS IN DERMATOLOGY, 1994, 12 (03) : 407 - 417
  • [35] TREATMENT OF SYSTEMIC-SCLEROSIS
    MEDSGER, TA
    [J]. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 1989, 15 (03) : 513 - 531
  • [36] JUVENILE SYSTEMIC-SCLEROSIS
    MARTINEZCORDERO, E
    FONSECA, MD
    LEON, DEA
    PADILLA, A
    [J]. JOURNAL OF RHEUMATOLOGY, 1993, 20 (02) : 405 - 407
  • [37] PHOTOPHERESIS AND SYSTEMIC-SCLEROSIS
    ZACHARIAE, H
    BJERRING, P
    HEICKENDORFF, L
    MOLLER, B
    WALLEVIK, K
    [J]. ARCHIVES OF DERMATOLOGY, 1992, 128 (12) : 1651 - 1652
  • [38] PREGNANCY AND SYSTEMIC-SCLEROSIS
    GIORDANO, M
    VALENTINI, G
    LUPOLI, S
    GIORDANO, A
    [J]. ARTHRITIS AND RHEUMATISM, 1985, 28 (02): : 237 - 238
  • [39] CUTANEOUS VITAMIN-D3 FORMATION IN PROGRESSIVE SYSTEMIC-SCLEROSIS
    MATSUOKA, LY
    DANNENBERG, MJ
    WORTSMAN, J
    HOLLIS, BW
    JIMENEZ, SA
    VARGA, J
    [J]. JOURNAL OF RHEUMATOLOGY, 1991, 18 (08) : 1196 - 1198
  • [40] THE PATHOGENESIS OF SYSTEMIC-SCLEROSIS
    LEROY, EC
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 1989, 7 : S135 - S137